Martingale Asset Management L P Takes Position in Intuitive Surgical, Inc. $ISRG

Key Points

• Martingale Asset Management L P has acquired 4,120 shares of Intuitive Surgical, valued at approximately $2.04 million, marking a new position in the medical equipment provider.
• Intuitive Surgical has been positively rated by analysts, with thirteen analysts
• Insider trading has seen significant activity, with insiders selling a total of 15,839 shares over the past three months, representing a notable decrease in their ownership stakes.

Martingale Asset Management L P acquired a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 4,120 shares of the medical equipment provider's stock, valued at approximately $2,041,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of ISRG. Brighton Jones LLC grew its stake in Intuitive Surgical by 24.9% during the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock worth $1,916,000 after purchasing an additional 731 shares in the last quarter. Bank Pictet & Cie Europe AG lifted its holdings in shares of Intuitive Surgical by 0.5% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 190,969 shares of the medical equipment provider's stock valued at $99,678,000 after purchasing an additional 883 shares during the last quarter. Burling Wealth Partners LLC purchased a new stake in shares of Intuitive Surgical in the 4th quarter valued at about $584,000. Integrated Wealth Concepts LLC lifted its holdings in shares of Intuitive Surgical by 14.7% in the 4th quarter. Integrated Wealth Concepts LLC now owns 5,530 shares of the medical equipment provider's stock valued at $2,886,000 after purchasing an additional 709 shares during the last quarter. Finally, Topsail Wealth Management LLC purchased a new stake in Intuitive Surgical during the 4th quarter valued at approximately $290,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on the company. Deutsche Bank Aktiengesellschaft downgraded Intuitive Surgical from a "hold" rating to a "sell" rating and reduced their price objective for the company from $515.00 to $440.00 in a research note on Monday, June 9th. Wall Street Zen raised shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Erste Group Bank reaffirmed a "hold" rating on shares of Intuitive Surgical in a report on Wednesday, July 23rd. BTIG Research boosted their target price on Intuitive Surgical from $566.00 to $571.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Finally, UBS Group boosted their target price on Intuitive Surgical from $547.00 to $585.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Thirteen research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $595.95.

Intuitive Surgical Stock Down 1.6%

Shares of ISRG traded down $7.72 on Monday, reaching $468.44. The stock had a trading volume of 1,660,747 shares, compared to its average volume of 1,980,700. The firm has a market capitalization of $167.93 billion, a PE ratio of 65.33, a PEG ratio of 4.99 and a beta of 1.59. The firm has a 50-day moving average of $503.41 and a 200 day moving average of $520.32. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.93 by $0.26. The business had revenue of $2.44 billion for the quarter, compared to analysts' expectations of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The company's revenue was up 21.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.78 EPS. On average, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Myriam Curet sold 4,500 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the sale, the executive vice president owned 353 shares in the company, valued at approximately $173,845.44. This represents a 92.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction on Friday, June 6th. The stock was sold at an average price of $563.11, for a total value of $121,631.76. Following the sale, the senior vice president owned 907 shares in the company, valued at $510,740.77. This trade represents a 19.23% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,839 shares of company stock worth $7,896,972. 0.70% of the stock is owned by insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.